Loading…
Loading…
Amesite (AMST) ripped 250% in premarket trading Tuesday after the AI software company secured a new enterprise customer representing an approximately 2,700-pati
Amesite shares jumped 90.82% after hours after announcing a major enterprise deployment and reporting strong year-over-year revenue growth.
Enterprise Deployment Validates AI-Native Infrastructure Strategy and Proves Scalable, Cost-Efficient Execution in Non-Acute Care Enterprise Deployment Validates AI-Native Infrastructure Strategy and Proves Scalable, Cost-Efficient Execution in Non-Acute Care
$2.6 million upfront with up to approximately $5.2 million of potential aggregate proceeds upon the exercise in full of warrants $2.6 million upfront with up to approximately $5.2 million of potential aggregate proceeds upon the exercise in full of warrants
DETROIT, April 28, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST), developer of the AI‑native NurseMagic™ platform and EMR for non‑acute care, today announced that it has entered into definitive agreements with certain of its officers and directors, including Dr. Ann Marie Sastry, Ph.D, its Chairman and CEO, and George Parmer, a member of its board of directors, for the purchase and sale of an aggregate of 418,118 shares of its common stock, Series A-1 warrants to purchase an aggregate up to 418,118 shares of the Company's common stock and Series A-2 warrants to purchase an aggregate up to 418,118 shares of the Company's common stock at a purchase price of $1.435 per share and accompanying warrants. The private placement follows the Company's recently announced concurrent registered direct offering and private placement, priced at-the-market under Nasdaq rules, which is expected to result in aggregate gross proceeds to the Company of approximately $2 million, before deducting placement agent fees and other offering expenses.
DETROIT, April 27, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST), developer of the AI‑native NurseMagic™ platform and EMR for non‑acute care, today announced that it has entered into definitive agreements for the purchase and sale of 696,866 shares of its common stock, at a purchase price of $1.435 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, the Company has agreed to issue to the investor unregistered Series A-1 warrants to purchase up to 696,866 shares of common stock and unregistered Series A-2 warrants to purchase up to 696,866 shares of common stock.
DETROIT, April 27, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST) (the “Company”), a leading developer of AI-powered enterprise solutions, today announced that it has filed with the U.S. Securities and Exchange Commission (the “SEC”) a request for withdrawal of the Company's Registration Statement on Form S-1 (No. 333-295187) originally filed on April 20, 2026 (the “Registration Statement”), as the Company no longer intends to pursue a public offering under the Registration Statement at this time.
Amesite Inc. (NASDAQ: AMST - Get Free Report) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totaling 105,758 shares, an increase of 63.7% from the March 15th total of 64,610 shares. Based on an average daily trading volume, of 26,298 shares, the days-to-cover ratio